A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysisWoolthuis, C. M., Mulder, A. B., Verkaik-Schakel, R. N., Rosati, S., Diepstra, A., van den Berg, E., Schuringa, J. J., Vellenga, E., Kluin, P. M. & Huls, G., Oct-2013, In : Haematologica. 98, 10, p. 1532-1538 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Mutations of nucleophosmin 1 are frequently found in acute myeloid leukemia and lead to aberrant cytoplasmic accumulation of nucleophosmin protein. Immunohistochemical staining is therefore recommended as the technique of choice in front-line screening. In this study, we assessed the sensitivity and specificity of immunohistochemistry on formalin-fixed bone marrow biopsies compared with gold standard molecular analysis to predict nucleophosmin 1 mutation status in 119 patients with acute myeloid leukemia. Discrepant cases were further characterized by gene expression analyses and fluorescence in situ hybridization. A large overlap between both methods was observed. Nevertheless, nine patients demonstrated discordant results at initial screening. Five cases demonstrated nuclear staining of nucleophosmin 1 by immunohistochemistry, but a nucleophosmin 1 mutation by molecular analysis. In two cases this could be attributed to technical issues and in three cases minor subpopulations of myeloblasts had not been discovered initially. All tested cases exhibited the characteristic nucleophosmin-mutated gene expression pattern. Four cases had cytoplasmic nucleophosmin 1 staining and a nucleophosmin-mutated gene expression pattern without a detectable nucleophosmin 1 mutation. In two of these cases we found the chromosomal translocation t(3;5)(q25;q35) encoding the NPM-MLF1 fusion protein. In the other discrepant cases the aberrant cytoplasmic nucleophosmin staining and gene expression could not be explained. In total six patients (5%) had true discordant results between immunohistochemistry and mutation analysis. We conclude that cytoplasmic nucleophosmin localization is not always caused by a conventional nucleophosmin 1 mutation and that in the screening for nucleophosmin 1 abnormalities, most information will be obtained by combining immunohistochemistry with molecular analysis.
|Number of pages||7|
|Publication status||Published - Oct-2013|
- ACUTE MYELOGENOUS LEUKEMIA, CYTOPLASMIC NUCLEOPHOSMIN, NORMAL KARYOTYPE, FAVORABLE PROGNOSIS, GENE-MUTATIONS, NPM1 MUTATION, NPMC(+) AML, EXPRESSION, CLASSIFICATION, LOCALIZATION